Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 10, 2010, Pages 1950-1958

  Van Der Veldt, Astrid A M ^a   Hendrikse, N Harry ^a   Smit, Egbert F ^a   Mooijer, Martien P J ^a   Rijnders, Anneloes Y ^a   Gerritsen, Winald R ^a   Van Der Hoeven, Jacobus J M ^b   Windhorst, Albert D ^a   Lammertsma, Adriaan A ^a   Lubberink, Mark ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Northwest Clinics   (Netherlands)

Author keywords

11C docetaxel; Biodistribution; Cancer. PET CT; Radiation Dose

Indexed keywords

CARBON 11; DOCETAXEL; CARBON; DIAGNOSTIC AGENT; TAXOID;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRAIN; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG LABELING; DRUG UPTAKE; FEMALE; GALLBLADDER; HUMAN; LIVER; LUNG; MALE; POSITRON EMISSION TOMOGRAPHY; RADIATION ABSORPTION; SOLID TUMOR; BLOOD; CLINICAL TRIAL; DRUG TOXICITY; METABOLIC CLEARANCE RATE; METABOLISM; NEOPLASM; RADIATION DOSE; RADIOGRAPHY; RADIOMETRY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

AGED; BIOLOGICAL TRANSPORT; CARBON RADIOISOTOPES; DRUG TOXICITY; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RADIOMETRY; TAXOIDS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79952109774     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-010-1489-y     Document Type: Article

References (30)

1. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-3.
2. Van der Veldt AA, Luurtsema G, Lubberink M, Lammertsma AA, Hendrikse NH. Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistance. Curr Pharm Des 2008;14:2914-31.
3. Van der Veldt AA, Lammertsma AA, Hendrikse NH. [11C]docetaxel and positron emission tomography for noninvasive measurements of docetaxel kinetics. Clin Cancer Res 2007;13:7522-3.
4. Van Tilburg EW, Franssen EJ, Van der Hoeven JJ, Van der Meij M, Elshove D, Lammertsma AA, et al. Radiosynthesis of [11C] docetaxel. J Labelled Comp Radiopharm 2004;47:763-77.
5. Van Tilburg EW, Mooijer MP, Brinkhorst J, Van der Meij M, Windhorst AD. Improved and semi-automated GMP-compliant radiosynthesis of [11C]docetaxel. Appl Radiat Isot 2008;66: 1414-8.
6. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005;6:229-39.
7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
8. Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp JS. Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med 2007;48:471-80.
9. Hoekstra CJ, Hoekstra OS, Lammertsma AA. On the use of the injection catheter for venous blood sampling in quantitative FDG PET studies. Eur J Nucl Med 2000;27:1579.
10. International Commission on Radiological Protection. Report of the Task Group on Reference Man. ICRP Publication 23. New York: Pergamon; 1975.
11. Cristy M, Eckerman KF. Specific absorbed fractions of energy at various ages from internal photon sources. Oak Ridge: Oak Ridge National Laboratory; 1987.
12. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023-7.
13. International Commission on Radiological Protection. Limits for intakes of radionuclides by workers. ICRP Publication 30. New York: Pergamon; 1979.
14. International Commission on Radiological Protection. The 1990 Recommendations. Ann ICRP 1991;21:1-3.
15. International Commission on Radiological Protection. The 2007 Recommendations. Ann ICRP 2007;37:2-4.
16. Hirvonen J, Roivainen A, Virta J, Helin S, Någren K, Rinne JO. Human biodistribution and radiation dosimetry of 11C-(R)-PK11195, the prototypic PET ligand to image inflammation. Eur J Nucl Med Mol Imaging 2010;37:606-12.
17. International Commission on Radiological Protection. Radiological protection in biomedical research. ICRP Publication 62. New York: Pergamon; 1991.
18. FDA. Food and Drug Administration Code of Federal Regulations. 21 CFR 361-1. 1991.
19. Rosing H, Lustig V, Van Warmerdam LJ, Huizing MT, Ten Bokkel Huinink WW, Schellens JH, et al. Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Cancer Chemother Pharmacol 2000;45:213-8.
20. Liu N, Li M, Li X, Meng X, Yang G, Zhao S, et al. PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans. J Nucl Med 2009;50:303-8.
21. Slifstein M, Hwang DR, Martinez D, Ekelund J, Huang Y, Hackett E, et al. Biodistribution and radiation dosimetry of the dopamine D2 ligand 11C-raclopride determined from human whole-body PET. J Nucl Med 2006;47:313-9.
22. Kalen JD, Hirsch JI, Kurdziel KA, Eckelman WC, Kiesewetter DO. Automated synthesis of 18F analogue of paclitaxel (PAC): [18F]paclitaxel (FPAC). Appl Radiat Isot 2007;65:696-700.
23. Kiesewetter DO, Jagoda EM, Kao CH, Ma Y, Ravasi L, Shimoji K, et al. Fluoro-, bromo-, and iodopaclitaxel derivatives: synthesis and biological evaluation. Nucl Med Biol 2003;30:11-24.
24. Kurdziel KA, Kalen JD, Hirsch JI, Wilson JD, Agarwal R, Barrett D, et al. Imaging multidrug resistance with 4-[18F]fluoropaclitaxel. Nucl Med Biol 2007;34:823-31.
25. Burris H, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer D, et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993;11:950-8.
26. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and cross-reactivity of one antibody with a muscle protein. J Histochem Cytochem 1989;37:159-64.
27. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987;84:7735-8.
28. Fojo T, Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 2007;18:v3-8.
29. Sanson M, Napolitano M, Yaya R, Keime-Guibert F, Broët P, Hoang-Xuan K, et al. Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study. J Neurooncol 2000;50:245-9.
30. Bart J, Groen HJ, Van der Graaf WT, Hollema H, Hendrikse NH, Vaalburg W, et al. An oncological view on the blood-testis barrier. Lancet Oncol 2002;3:357-63.